Quantcast
Last updated on April 20, 2014 at 14:04 EDT

Latest neck cancers Stories

2012-06-20 02:26:31

CALGARY, June 20, 2012 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX: ONC) NASDAQ: ONCY) announced today that the Company's independent Data Monitoring Committee (DMC) has reviewed the safety data for the first stage of its Phase III trial of REOLYSIN in combination with carboplatin and paclitaxel for the treatment of head and neck cancers (REO 018). Based on the review of the safety data the DMC has recommended that enrollment continue in the study. "The safety data...

2012-06-02 02:20:16

CHICAGO, June 2, 2012 /PRNewswire/ -- -- TLE3 Biomarker Over-expressed in HER2-positive, Hormone Receptor-positive, and Triple-negative Breast Cancers -- -- EGFR status May Facilitate Therapeutic Decision-making in Head and Neck Cancer -- Caris Life Sciences announced today the utility of the company's Caris Target Now(TM) evidence-based molecular profiling service in the characterization of breast and head and neck cancers. These data were presented today at the...

2012-05-10 02:31:05

CALGARY, May 10, 2012 /PRNewswire/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced its financial results and operational highlights for the quarter ended March 31, 2012. "In early April, 2012, we announced that we had completed enrollment in the first, 80-patient stage of our Phase III trial in head and neck cancers.  The analysis of this patient group will be a significant milestone," said Dr. Brad Thompson, President and CEO of...

2012-04-03 02:25:32

NEW YORK, April 3, 2012 /PRNewswire/ -- Popular recording artist, actor and former member of The Monkees, Peter Tork, who is himself an oral cancer survivor, is urging Americans to get screened for cancer during the 15(th) annual Oral, Head & Neck Cancer Awareness Week(®) (OHANCAW(®)), being held nationwide April 22-28. More than 200 sites throughout the country will offer free oral, head and neck cancer screenings during OHANCAW, which is sponsored by the Head and Neck Cancer...

2012-04-02 02:27:40

CALGARY, April 2, 2012 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that it has completed enrollment in the first, 80 patient stage of its Phase III clinical trial examining REOLYSIN(®) in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers (REO 018). "This is an important milestone for this study," said Dr. Brad Thompson, President and CEO of Oncolytics. "A data analysis that will...

2012-03-22 02:24:46

SAN DIEGO, March 22, 2012 /PRNewswire/ -- OncoSec Medical Incorporated. (OTCBB:ONCS), which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumor cancers, today announced that the company has been selected to present data from its Phase III and IV head and neck cancer studies at two upcoming conferences. Data from the Phase IV study carried out in Europe has been selected for a poster session and special oral presentation at the 5th...

2012-03-15 06:00:00

CALGARY, March 15, 2012 /PRNewswire/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced its financial results and operational highlights for the year ended December 31, 2011. "In the last year we made substantial progress as we announced positive clinical trial results and started clinical trials in additional cancer indications while maintaining the strength of our balance sheet," said Dr. Brad Thompson, President and CEO of Oncolytics....

2012-01-26 13:35:37

Research physicians from Georgetown Lombardi Comprehensive Cancer Center will present new data about a complex group of cancers known as head and neck cancers at the Multidisciplinary Head and Neck Cancer Symposium, January 26 through 28, in Phoenix, Arizona. Should patients with HPV+ head and neck cancers receive less chemotherapy? Georgetown researchers are examining a hypothesis about whether HPV+ patients with a head and neck cancer should receive more or less chemotherapy....

2012-01-23 21:55:05

Researchers at Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center, the University Hospital for Einstein, have found a biomarker in head and neck cancers that can predict whether a patient's tumor will be life threatening. The biomarker is considered particularly promising because it can detect the level of risk immediately following diagnosis. This discovery could become a component of a new test to guide how aggressively those with head and neck tumors...

2011-11-14 06:00:00

CALGARY, Nov. 14, 2011 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced that positive results from a Phase 2 clinical trial (REO 015) using intravenous administration of REOLYSIN(®) in combination with paclitaxel and carboplatin in patients with advanced head and neck cancers will be presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The conference is being held in San...